Johnson & Johnson (NYSE:JNJ) Stake Raised by FFT Wealth Management LLC

FFT Wealth Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 9.9% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,973 shares of the company’s stock after purchasing an additional 269 shares during the period. FFT Wealth Management LLC’s holdings in Johnson & Johnson were worth $430,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in JNJ. IFS Advisors LLC grew its position in Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in shares of Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson in the 3rd quarter worth $35,000. Bay Harbor Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $32,000. Finally, Activest Wealth Management purchased a new stake in shares of Johnson & Johnson during the third quarter valued at $40,000. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of a number of analyst reports. Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Leerink Partners reduced their price target on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Barclays increased their target price on Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a report on Tuesday, January 28th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $170.67.

Insider Transactions at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the sale, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. The trade was a 2.60 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mark A. Weinberger purchased 1,000 shares of the stock in a transaction on Thursday, December 12th. The shares were bought at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.16% of the stock is currently owned by corporate insiders.

Johnson & Johnson Trading Up 0.9 %

Shares of NYSE JNJ opened at $165.23 on Friday. The business has a 50 day simple moving average of $150.90 and a 200 day simple moving average of $156.06. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $168.85. The stock has a market cap of $397.81 billion, a price-to-earnings ratio of 24.85, a PEG ratio of 2.56 and a beta of 0.52. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. The company’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.00%. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.